SEC Form SC 13G filed by Adverum Biotechnologies Inc.

10/30/24 9:34:20 PM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $ADVM alert in real time by email

SC 13G 1 13gplaintext.txt GUS STERN PLAIN TEXT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.) Adverum Biotechnologies, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 00773U207 (CUSIP Number) 10/29/2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ? Rule 13d-1(b) ?x Rule 13d-1(c) ? Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. CUSIP No. Page X of XX 1. Names of Reporting Persons. Augustus Stern, MD 2. Check the Appropriate Box if a Member of a Group (a) ? (b) ?x 3. SEC Use Only 4. Citizenship or Place of Organization USA Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power 1,116,628 6. Shared Voting Power 7. Sole Dispositive Power 1,116,628 8. Shared Dispositive Power 9. Aggregate Amount Beneficially Owned by Each Reporting Person 1,116,628 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares ? 11. Percent of Class Represented by Amount in Row (9) 5.37% 12. Type of Reporting Person IN CUSIP No. ITEM 1. (a) Name of Issuer: Adverum Biotechnologies, Inc. (b) Address of Issuer's Principal Executive Offices: 100 Cardinal Way, Redwood City, CA 94063 ITEM 2. (a) Name of Person Filing: Augustus Stern, MD (b) Address of Principal Business Office, or if None, Residence: 712 Childs Point Rd Annapolis, MD 21401 (c) Citizenship: USA (d) Title of Class of Securities: Common Stock, $0.0001 par value (e) CUSIP Number: 00773U207 ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SS.240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A: (a) [_] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o). (b) [_] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c). (c) [_] Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c). (d) [_] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a- 8). (e) [_] An investment adviser in accordance with ss.240.13d-1(b)(1)(ii)(E); (f) [_] An employee benefit plan or endowment fund in accordance with ss.240.13d-1(b)(1)(ii)(F); (g) [_] A parent holding company or control person in accordance with ss.240.13d-1(b)(1)(ii)(G); (h) [_] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) [_] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) [_] Group, in accordance with ss.240.13d-1(b)(1)(ii)(J). ITEM 4. OWNERSHIP. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: 1,116,628 (b) Percent of class: 5.37% (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote (ii) Shared power to vote or to direct the vote 1,116,628 0 (iii) Sole power to dispose or to direct the disposition of (iv) Shared power to dispose or to direct the disposition of 1,116,628 0 INSTRUCTION. For computations regarding securities which represent a right to acquire an underlying security SEE ss.240.13d3(d)(1). If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ]. INSTRUCTION: Dissolution of a group requires a response to this item. ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON. If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY. If a parent holding company or Control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP. If a group has filed this schedule pursuant to ss.240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to ss.240.13d-1(c) or ss.240.13d-1(d), attach an exhibit stating the identity of each member of the group. ITEM 9. NOTICE OF DISSOLUTION OF GROUP. Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5. (a) The following certification shall be included if the statement is filed pursuant to Rule 13d-1(b): "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect." (b) The following certification shall be included if the statement is filed pursuant to Rule 13d-1(c): "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect." SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. 10/30/2024 (Date) /s/ Augustus Stern, MD (Signature) individual (Name/Title) The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

Get the next $ADVM alert in real time by email

Date	Price Target	Rating	Analyst
6/25/2024	$25.00	Outperform	Oppenheimer
4/30/2024	$30.00	Buy	H.C. Wainwright
7/7/2022	$4.00	Hold → Buy	Truist
7/23/2021		Hold → Neutral	Cantor Fitzgerald
7/23/2021	$23.00 → $3.00	Overweight → Neutral	Cantor Fitzgerald
7/23/2021	$5.00 → $2.00	Market Perform	SVB Leerink

SEC Form SC 13G filed by Adverum Biotechnologies Inc.

Chat with this insight

Recent Analyst Ratings for $ADVM

$ADVM Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Chief Medical Officer Ozden Rabia Gurses

SEC Form 4 filed by CHIEF FINANCIAL OFFICER Rubinstein Linda M

SEC Form 4 filed by CHIEF DEVELOPMENT OFFICER Seyedkazemi Setareh

$ADVM Market Insights

Live Market Insights

More Than $10M Bet On Appian? Check Out These 3 Stocks Insiders Are Buying

Chardan Capital Maintains Buy on Adverum Biotechnologies, Adjusts Price Target To $40 ((reverse stock split 1:10))

Adverum Releases Interim Data From Gene Therapy Study For Blindness Disorder, Prepares For Pivotal Study

$ADVM Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Adverum Biotechnologies Inc.

Amendment: SEC Form SC 13G/A filed by Adverum Biotechnologies Inc.

Amendment: SEC Form SC 13G/A filed by Adverum Biotechnologies Inc.

$ADVM SEC Filings

Adverum Biotechnologies Inc. filed SEC Form 8-K: Regulation FD Disclosure

SEC Form 10-Q filed by Adverum Biotechnologies Inc.

Adverum Biotechnologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$ADVM Press Releases

Fastest customizable press release news feed in the world

$ADVM Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Adverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design Elements

Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements

Oppenheimer initiated coverage on Adverum Biotech with a new price target

H.C. Wainwright initiated coverage on Adverum Biotech with a new price target

Adverum Biotech upgraded by Truist with a new price target

$ADVM Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Large owner Leonard Braden Michael bought $613,470 worth of shares (85,800 units at $7.15) (SEC Form 4)

Large owner Leonard Braden Michael bought $1,785,662 worth of shares (216,264 units at $8.26) (SEC Form 4)

Scopa James Paul bought $135,000 worth of shares (100,000 units at $1.35) (SEC Form 4)

$ADVM Financials

Live finance-specific insights

Adverum Biotechnologies to Host Webcast to Review Clinical Data from the 26-Week Interim Analysis of the Ongoing LUNA Phase 2 Trial in Wet AMD Being Presented at ASRS Annual Meeting

Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024

Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society

$ADVM Leadership Updates

Live Leadership Updates

Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones

Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program

Adverum Biotechnologies Reports Second Quarter 2024 Financial Results and Provides Program and Corporate Highlights

Recent Analyst Ratings for
$ADVM

$ADVM
Insider Trading

$ADVM
Market Insights

$ADVM
Large Ownership Changes

$ADVM
SEC Filings

$ADVM
Press Releases

$ADVM
Analyst Ratings

$ADVM
Insider Purchases

$ADVM
Financials

$ADVM
Leadership Updates